Document Detail


Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
MedLine Citation:
PMID:  15015668     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. A local chemotherapy applied directly to the resection cavity may act directly on residual tumor cells in adjacent brain possibly leading to a local control of the tumor and increased survival. METHODS: We have analyzed the pattern of recurrence using serial MRI studies of 24 patients treated with GLIADEL Wafers or placebo wafers following resection of glioblastomas. RESULTS: Of 24 patients 11 received carmustine wafers and 13 placebo. The age distribution and Karnowsky performance scores of the two populations were not different. However, the median survival (14.7 versus 9.5 months; P = 0.007) and the time to neurological deterioration (12.9 +/- 4.85 vs. 9.4 +/- 2.73 months; P = 0.035) was significantly longer in the treatment group versus the placebo treated control. Preoperative and follow up MRI studies were evaluated in a blinded fashion. Out of 24 patients that entered the analysis 11 showed clearance of all contrast enhancement following resection of glioblastomas. Seventeen tumors progressed locally and 7 showed different patterns of distant failure. Within the carmustine treated group 8 patients showed a local treatment failure with recurrent tumors immediately adjacent to the resection cavity or progression form a residual tumor. Three patients showed a multifocal distant and local pattern of failure after complete or subtotal removal. In no case the local chemotherapy resulted in a distant recurrence only. However, the time to radiographic progression was 165.1 +/- 80.75 days for the GLIADEL Wafer group and 101.9 +/- 43.06 days for the placebo group (P = 0.023). CONCLUSION: In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time. Local chemotherapy with carmustine containing wafer implants did not result in an altered pattern of recurrence and did not promote multifocal patterns of recurrence.
Authors:
Alf Giese; Thomas Kucinski; Ulrich Knopp; Roland Goldbrunner; Wolfgang Hamel; H M Mehdorn; Jörg C Tonn; Dana Hilt; Manfred Westphal
Related Documents :
21615918 - Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences...
1587748 - Survival following locoregional recurrence of breast cancer: univariate and multivariat...
9409598 - Early aggressive treatment for merkel cell carcinoma improves outcome.
18785068 - Level of streptococcus pyogenes in patients with recurrent tonsillitis and tonsillar hy...
4052968 - Esophageal carcinoma metastatic to the stomach. a clinicopathologic study of 35 cases.
21615918 - Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  66     ISSN:  0167-594X     ISO Abbreviation:  J. Neurooncol.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-03-12     Completed Date:  2004-04-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  351-60     Citation Subset:  IM    
Affiliation:
Department of Neurosurgery, University Hospital Lübeck, Lübeck, Germany. alf.giese@neurochirurgie.mu-luebeck.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorbable Implants
Adolescent
Adult
Age Distribution
Aged
Antineoplastic Agents, Alkylating / therapeutic use*
Brain Neoplasms / drug therapy*,  pathology
Carmustine / therapeutic use*
Drug Implants
Glioblastoma / drug therapy*,  pathology
Humans
Middle Aged
Neoplasm Recurrence, Local / pathology*
Prospective Studies
Randomized Controlled Trials as Topic
Survival Rate
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 0/Drug Implants; 154-93-8/Carmustine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to ...
Next Document:  Unusual metastatic features in a patient with concomitant malignant orbital melanoma and prostate ca...